Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Biogen Inc. “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China June 27, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease June 09, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel June 03, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS May 30, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences May 22, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis May 16, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB IONS Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status May 14, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Reports Progress on Corporate Responsibility Priorities May 02, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy March 06, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB IONS Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting March 04, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP February 23, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia February 12, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen to Realign Resources for Alzheimer's Disease Franchise January 31, 2024 From Biogen Inc. Via GlobeNewswire Tickers BIIB Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission December 19, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease December 15, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. December 14, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB SAGE Biogen Appoints Monish Patolawala to its Board of Directors November 06, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On October 25, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease October 25, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting October 19, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA® September 29, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Completes Acquisition of Reata Pharmaceuticals September 26, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB RETA LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan September 25, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen Appoints Jane Grogan as Head of Research September 06, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder August 04, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB Biogen to Acquire Reata Pharmaceuticals July 28, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB RETA Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023 July 19, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease July 06, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy June 30, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB IONS Biogen Announces Changes to Its Board of Directors June 12, 2023 From Biogen Inc. Via GlobeNewswire Tickers BIIB Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.